Physician profile
Yin Wu
NPI 1053516401
$2,167.45
in general payments reported to CMS, 2019-2025
39 companies · $581 in 2025
The $581 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $100 · 2021: $65.61 · 2022: $145 · 2023: $376 · 2024: $595 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458 · Education: $94.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.29 |
| Education | $94.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $225.11 | 2019-2024 | Tecvayli, Darzalex, Talvey |
| Incyte Corporation | $175.97 | 2019-2023 | Monjuvi, Jakafi |
| Glaxosmithkline, LLC. | $135.73 | 2023-2025 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $135.46 | 2020-2025 | Iclusig, Fruzaqla, Ninlaro |
| Regeneron Healthcare Solutions, INC. | $126.57 | 2022-2025 | Libtayo |
| Tersera Therapeutics LLC | $125.61 | 2024-2025 | Zoladex, Xermelo |
| Pharmacyclics LLC, An Abbvie Company | $115.41 | 2020-2023 | Imbruvica |
| Daiichi Sankyo INC. | $103.20 | 2024-2025 | Injectafer |
| Pfizer INC. | $81.04 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $65.44 | 2019 | |
| Biocon Biologics INC | $60.01 | 2024-2025 | Ogivri |
| Astellas Pharma US INC | $57.66 | 2024-2025 | Vyloy, Padcev |
| Genentech USA, INC. | $53.10 | 2023-2024 | Polivy, Lunsumio, Columvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.34 | 2019-2024 | Spevigo |
| Sobi, INC | $42.43 | 2023-2024 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yin Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.